察觉
发表于 2025-3-23 11:19:49
http://reply.papertrans.cn/67/6685/668466/668466_11.png
BOON
发表于 2025-3-23 15:51:03
Adenosine A2A Receptor Antagonists,ches to dual A./A. antagonists and A./MAO-B will also be highlighted. The in vivo profiles of compounds will be highlighted and discussed to compare activities across different chemical series. A clinical report and update will be given on compounds that have entered clinical trials.
细丝
发表于 2025-3-23 19:37:08
,Targeting α-Synuclein as a Parkinson’s Disease Therapeutic,estigation that aim to maintain physiological α-synuclein levels, limit toxic aggregates, and lessen effects of misfolded α-synuclein on cellular homeostasis. For example, oligonucleotide-based approaches limit α-synuclein gene expression. In addition, select small molecules and peptides inhibit α-s
addict
发表于 2025-3-23 23:58:45
http://reply.papertrans.cn/67/6685/668466/668466_14.png
得体
发表于 2025-3-24 03:55:53
http://reply.papertrans.cn/67/6685/668466/668466_15.png
Cupidity
发表于 2025-3-24 07:20:12
Adenosine A2A Receptor Antagonists, still are, a promising non-dopaminergic approach for the potential treatment of Parkinson’s disease. There have been numerous publications, patent applications, and press releases that highlight new medicinal chemistry approaches to this attractive and promising target to treat Parkinson’s disease.
散布
发表于 2025-3-24 14:21:47
http://reply.papertrans.cn/67/6685/668466/668466_17.png
消毒
发表于 2025-3-24 18:25:25
http://reply.papertrans.cn/67/6685/668466/668466_18.png
NATTY
发表于 2025-3-24 20:20:57
nce of ‘big business’, with the Commission’s Directorate-General for Enterprise and Industry being in the firing line (e.g., ALTEREU, 2013). Interestingly, however, DG Enterprise’s work with the expert group discussed in this chapter proves quite the contrary. So far, this book has examined two expe
dragon
发表于 2025-3-25 01:13:23
6楼